The VanEck Biotech ETF (NASDAQ:BBH) provides a low-cost, concentrated play on large-cap biotech leaders, whereas Invesco Biotechnology & Genome ETF (NYSEMKT:PBE) uses a multifactor approach that has recently offered higher yields and slightly better five-year total returns. Both funds seek to capture the growth of the healthcare and genetic research sectors but employ distinct methodologies. VanEck Biotech ETF tracks an index of the 25 largest U.S.-listed biotech companies, while Invesco Biotechnology & Genome ETF uses a quantitative selection process to identify 30 stocks with favorable growth and momentum characteristics. Beta measures price volatility relative to the S&P 500; beta is calculated from monthly returns over the available fund history (up to five years). The 1-yr return represents total return over the trailing 12 months. Dividend yield is the trailing-12-month distribution yield.
CryptoAlerta — análise de criptomoedas e mercado em tempo real